In The News Posted March 16, 2019 Share Posted March 16, 2019 NEW ORLEANS, March 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the results of the randomized PARTNER 3 Trial demonstrated superiority... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.